188 related articles for article (PubMed ID: 34551033)
1. Serum Visfatin as a Diagnostic Marker of Active Inflammatory Bowel Disease.
Saadoun MM; Nosair NAE; Abdel-Azeez HA; Sharaf SM; Ahmed MH
J Gastrointestin Liver Dis; 2021 Sep; 30(3):339-345. PubMed ID: 34551033
[TBL] [Abstract][Full Text] [Related]
2. Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia.
Neubauer K; Bednarz-Misa I; Walecka-Zacharska E; Wierzbicki J; Agrawal A; Gamian A; Krzystek-Korpacka M
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621173
[TBL] [Abstract][Full Text] [Related]
3. Serum adipokines in inflammatory bowel disease.
Waluga M; Hartleb M; Boryczka G; Kukla M; Zwirska-Korczala K
World J Gastroenterol; 2014 Jun; 20(22):6912-7. PubMed ID: 24944482
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
[TBL] [Abstract][Full Text] [Related]
5. Red cell distribution width for assessment of activity of inflammatory bowel disease.
Cakal B; Akoz AG; Ustundag Y; Yalinkilic M; Ulker A; Ankarali H
Dig Dis Sci; 2009 Apr; 54(4):842-7. PubMed ID: 18716874
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
7. Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan.
Yasuda R; Arai K; Kudo T; Nambu R; Aomatsu T; Abe N; Kakiuchi T; Hashimoto K; Sogo T; Takahashi M; Etani Y; Kato K; Yamashita Y; Mitsuyama K; Mizuochi T
J Gastroenterol Hepatol; 2023 Jul; 38(7):1131-1139. PubMed ID: 36880154
[TBL] [Abstract][Full Text] [Related]
8. Level of interleukin 17 in inflammatory bowel disease and its relation with disease activity.
Menesy A; Hammad M; Aref S; Abozeid FAM
BMC Gastroenterol; 2024 Apr; 24(1):135. PubMed ID: 38622545
[TBL] [Abstract][Full Text] [Related]
9. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease.
Farias E Silva K; Nanini HF; Cascabulho CM; Rosas SLB; Santana PT; Carneiro AJV; Anaissie E; Nucci M; de Souza HSP
World J Gastroenterol; 2021 Mar; 27(9):866-885. PubMed ID: 33727775
[TBL] [Abstract][Full Text] [Related]
10. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
Terzoudis S; Malliaraki N; Damilakis J; Dimitriadou DA; Zavos C; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):814-9. PubMed ID: 26934527
[TBL] [Abstract][Full Text] [Related]
11. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
12. Increased serum nesfatin-1 levels in patients with inflammatory bowel diseases.
Beyaz Ş; Akbal E
Postgrad Med J; 2022 Jun; 98(1160):446-449. PubMed ID: 33541923
[TBL] [Abstract][Full Text] [Related]
13. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.
Kalla R; Kennedy NA; Ventham NT; Boyapati RK; Adams AT; Nimmo ER; Visconti MR; Drummond H; Ho GT; Pattenden RJ; Wilson DC; Satsangi J
Am J Gastroenterol; 2016 Dec; 111(12):1796-1805. PubMed ID: 27596694
[TBL] [Abstract][Full Text] [Related]
14. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
15. Pancreatitis-associated protein does not predict disease relapse in inflammatory bowel disease patients.
Nunes T; Etchevers MJ; Sandi MJ; Pinó Donnay S; Grandjean T; Pellisé M; Panés J; Ricart E; Iovanna JL; Dagorn JC; Chamaillard M; Sans M
PLoS One; 2014; 9(1):e84957. PubMed ID: 24416322
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
Yang Z; Clark N; Park KT
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
[TBL] [Abstract][Full Text] [Related]
17. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease.
Suárez Ferrer C; Abadía Barno M; Martín Arranz E; Jochems A; García Ramírez L; Poza Cordón J; Jaquotot Herranz M; Cerpa Arencibia A; Martín Arranz MD
Rev Esp Enferm Dig; 2019 Oct; 111(10):744-749. PubMed ID: 31476872
[TBL] [Abstract][Full Text] [Related]
18. Platelet/Albumin ratio and plateletcrit levels are potential new biomarkers for assessing endoscopic inflammatory bowel disease severity.
Huang J; Lu J; Jiang F; Song T
BMC Gastroenterol; 2023 Nov; 23(1):393. PubMed ID: 37964205
[TBL] [Abstract][Full Text] [Related]
19. Laboratory values in Japanese children with newly diagnosed inflammatory bowel disease.
Takaki Y; Mizuochi T; Eda K; Ishihara J; Yamashita Y
Pediatr Int; 2019 Jul; 61(7):720-725. PubMed ID: 31102555
[TBL] [Abstract][Full Text] [Related]
20. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
